Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is making it clear—he wants a closer look at the safety of the abortion pill mifepristone.
In a recent interview on Fox News, he emphasized his commitment to investigating potential risks linked to the drug, following directives from President Donald Trump.
A Presidential Directive to Investigate
Kennedy, who was narrowly confirmed by the Senate just last Thursday, told Fox News host Laura Ingraham that Trump has specifically asked him to examine safety concerns surrounding mifepristone.
While the abortion pill has been available for years, Kennedy expressed concerns over the lack of strict reporting requirements for nonfatal complications.
“What [Trump has] asked me to do is study the … safety signals, and I think that that’s worth doing,” Kennedy explained on The Ingraham Angle.
Criticism of Reporting Policies
One of Kennedy’s biggest concerns is the National Institutes of Health (NIH) policy on reporting side effects.
He criticized the agency for not requiring doctors to document nonfatal complications related to mifepristone, calling it “inexcusable.”
“The NIH did something that was inexcusable — which is to tell doctors and patients not to report injuries,” Kennedy stated. “That’s not a good policy.”
A Commitment Made During Confirmation Hearings
This isn’t the first time Kennedy has spoken out about the issue.
During his Senate confirmation hearings, he promised to investigate mifepristone’s safety when questioned by Republican Sen. Steve Daines of Montana.
“I think it’s immoral to have a policy where patients are not allowed to report adverse events, or doctors are discouraged from doing that,” Kennedy said in late January.
He also clarified that while Trump has asked him to conduct a safety review, the president has yet to take a stance on potential regulations.
“Whatever he does [take a position], I will implement those policies,” Kennedy added.
Overseeing Key Health Agencies
As the head of HHS, Kennedy now has direct oversight of major health agencies, including the NIH, the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).
His new role gives him the authority to push for more transparency in drug safety reporting—a move that could lead to significant policy changes in the months ahead.
With the abortion pill already a heated topic in national politics, Kennedy’s investigation is sure to draw strong reactions from both sides of the debate.
This article was published on TDPel Media. Thanks for reading!Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn